20:54 , May 20, 2019 |  BC Innovations  |  Distillery Therapeutics

Aubagio and other DHODH inhibitors as epilepsy therapies

DISEASE CATEGORY: Neurology INDICATION: Epilepsy Patient sample, cell culture and mouse studies suggest inhibiting DHODH could help treat epilepsy. Metabolic modeling of transcriptome data from the cortex and hippocampus of epilepsy patients and two rat...
22:45 , Apr 12, 2019 |  BioCentury  |  Emerging Company Profile

Bright Angel: New hope against fungal resistance

Bright Angel is tackling antifungal resistance at its root with inhibitors of Hsp90 and other stress response factors, unlike competitors that are developing compounds against known or new pathways where resistance can still emerge. Resistance...
23:18 , Feb 1, 2019 |  BioCentury  |  Product Development

Year of the lion

With three data readouts coming in 2019, Aslan Pharmaceuticals Ltd. is hoping this will be the year it starts to reap the benefits of its 2012 strategy rethink, giving the biotech more options for advancing...
01:35 , Feb 1, 2019 |  BC Week In Review  |  Company News

Ahead of 2019 milestones, Aslan reduces headcount, operating costs

Aslan Pharmaceuticals Ltd. (TPEx:6497; NASDAQ:ASLN) said late Jan. 29 it will reduce headcount by 30% and slash operating costs by 50%. The restructuring will help support Aslan well into 2020 as it focuses operations on...
23:00 , Jan 29, 2019 |  BC Extra  |  Company News

Aslan to reduce headcount, operating costs to support upcoming milestones

Aslan Pharmaceuticals Ltd. (TPEx:6497; NASDAQ:ASLN) said late Tuesday it will reduce headcount by 30% and slash operating costs by 50%. The restructuring will help support Aslan well into 2020 as it focuses operations on its...
19:02 , Jan 11, 2019 |  BC Week In Review  |  Company News

Immunic plans to go public via Vital Therapies

Vital Therapies Inc. (NASDAQ:VTL) will acquire all outstanding shares of Immunic AG (Martinsried, Germany). The resulting company, which will retain Immunic's name and trade on NASDAQ, will develop Immunic’s pipeline, including IMU-838, a molecule inhibitor...
23:54 , Apr 26, 2018 |  BC Innovations  |  Targets & Mechanisms

Raising metabolism

In the wake of the failure of ECHO-301, drug developers are asking whether the trial design or the target is at fault. But while the value of IDO1 as a target is still in doubt,...
22:56 , Apr 10, 2018 |  BC Innovations  |  Distillery Therapeutics

Cancer

INDICATION: Melanoma Cell culture and mouse studies identified p53-activating tetrahydroindazole-based DHODH inhibitors that could help treat melanoma. Screening of a small molecule library in human melanoma cell line-based assays of p53-dependent transcription, followed by chemical...
21:34 , Feb 28, 2018 |  BC Extra  |  Financial News

Celgene's slide continues after refusal to file letter

Celgene Corp. (NASDAQ:CELG) shed $8.66 to $87.12 on Wednesday after FDA issued a refusal to file letter for an NDA for ozanimod (RPC1063) to treat multiple sclerosis. The news was announced after market close Tuesday...
00:04 , Dec 1, 2017 |  BC Week In Review  |  Financial News

Step Pharma adds €8.6M to series A

Autoimmune play Step Pharma S.A.S. (Paris, France) raised €8.6 million ($10.2 million) in the second and final close of a series A round, bringing the total to €14.5 million ($17.1 million). New investor Pontifax Group...